Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Tsang TK, Walker R, Yu DJ
mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation
Findings suggest this interaction may trigger signal cascades involving second messengers such as cAMP, leading to downstream transcriptional activity related to GH synthesis
$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore'] FIGURE: 1 / 1 Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties
Zhou B, Hao Q, Liang Y, Kong E
While bacteriostatic water is more temperature-stable than reconstituted peptide solutions, prolonged heat exposure during extended shipping can still affect quality
